The questions we want to ask the Minister, and it has been touched on in second reading, is he certain that there need be no requirements—and my colleague Simon Watts raised points of this type as well—no provisions, or it is not necessary to have provisions to review this Act at some point in the future? Let's remember it hasn't had a New Zealand Bill of Rights Act (BORA) vet, it hasn't had a regulatory impact statement (RIS), it hasn't had an impact analysis, and even though the therapeutic products bill is promised, it is some point in the future and doesn't really address these questions that we'd have with any other normal legislative process. So I'm just looking for some reassurance from him or reasons as to why not or that maybe it could be considered.